SUBSCRIBE
SUBSCRIBE

California

Businessmen grasping cardboard box full of office supplies on a desk in an office
IPO
Metagenomi CSO Steps Down Shortly After IPO, Moderna Exit
Following a disappointing IPO and the loss of Moderna’s gene editing contract, Metagenomi’s Chief Scientific Officer Luis Borges is departing the biotech.
July 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Tampa, Florida
Drug Development
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors
Amgen has quietly discontinued the development of its Phase I bispecific T-cell engager AMG 794, which the company had been studying for several malignant solid tumors.
July 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Medicine vial over rock pile with comple
Drug Development
Gilead’s Trodelvy Stumbles in Late-Stage Trials But Remains Prized Cancer Asset
Gilead Sciences’ blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space.
June 28, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Woman carrying box of office things
Business
BIO24 Kicks Off in San Diego as City’s Biotech Hub Gets Hit with Jobs Downturn
While San Diego remains a top biotech hub behind Boston and San Francisco, the city—which hosts this week’s BIO International Convention—has seen employment drop amid economic headwinds.
June 3, 2024
 · 
5 min read
 · 
Tyler Patchen
Load More
PRESS RELEASES
Press Releases
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
December 8, 2025
 · 
9 min read
Press Releases
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 8, 2025
 · 
7 min read
Press Releases
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 8, 2025
 · 
5 min read
Press Releases
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 8, 2025
 · 
1 min read
Press Releases
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 8, 2025
 · 
13 min read
Press Releases
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
December 8, 2025
 · 
7 min read
Press Releases
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 8, 2025
 · 
19 min read
Press Releases
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 8, 2025
 · 
5 min read
Press Releases
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
December 8, 2025
 · 
6 min read
Press Releases
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 8, 2025
 · 
6 min read
Press Releases
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 8, 2025
 · 
10 min read
Press Releases
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 8, 2025
 · 
17 min read
Press Releases
Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting
December 8, 2025
 · 
8 min read
Press Releases
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
December 8, 2025
 · 
11 min read
Press Releases
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
December 8, 2025
 · 
6 min read
Press Releases
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 8, 2025
 · 
8 min read
Press Releases
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
 · 
5 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
 · 
4 min read
Press Releases
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
 · 
2 min read
Press Releases
Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome
December 8, 2025
 · 
8 min read
Load More